MAP2K7 and melanoma: Moreover, a combination of an eIF4F inhibitor with vemurafenib and cobimetinib prevented the emergence of persister melanoma cells that can tolerate the exposure to lethal concentrations of the BRAF and MEK inhibitors (12).